《大行報告》大和首予榮昌生物-B(09995.HK)「跑贏大市」評級 目標價100元
大和發表研究報告,指出榮昌生物(09995.HK)的自主研發抗體偶聯藥物(ADC)候選產品RC48,是用於治療人類表皮生長因子受體2(HER2)的國內首款本土ADC,未來有對外授權的可能,首次給予「跑贏大市」評級,目標價100元。
該行指出,公司於去年8月就RC48提交新藥上市申請,預期將於今年第二季獲批上市,估計至2027年峰值收入可達55億元人民幣。
大和指,另一款候選產品融合蛋白RC28,目前正進行對視網膜病變等多種眼科疾病的臨床研究評估,預期就濕性老年性黃斑病變(wAMD)的治療將最先於2023年獲批,並估計至2029年峰值銷售收入可達15億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.